Jakavi 5mg (Ruxolitinib)
₨ 217,000
Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
Related Products
Glivec (imatinib mesylate) is indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
Tasigna 200mg (nilotinib) is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with
newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Tasigna 200mg (nilotinib) is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with
newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early
breast cancer.
Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
Glivec (imatinib mesylate) is indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Reviews
There are no reviews yet.